Ganciclovir treatment of life-or sight-threatening cytomegalovirus infection: Experience in 314 immunocompromised patients

Reviews of Infectious Diseases

Volumn 10, Issue , 1988, Pages S495-S506

  Buhles, W C ^a   Mastre, B J ^a   Tinker, A J ^a   Strand, V ^a   Koretz, S H ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; GASTROENTERITIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; MALE; PRESCHOOL CHILD; RETINITIS; VIRUS PNEUMONIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GASTROENTERITIS; HUMAN; IMMUNE TOLERANCE; INFANT; MALE; MIDDLE AGE; PNEUMONIA, VIRAL; RETINITIS;

EID: 0024040718     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/10.Supplement_3.S495     Document Type: Article

References (20)

1. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(l, 3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314:801-5.
2. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(l, 3-di-hydroxy-2-propoxymethyl)guanine. J Infect Dis 1985; 152: 833-4.
3. Verheyden JPH. Evolution of therapy for cytomegalovirus infection. Rev Infect Dis 1988;10(Suppl 3): S477-89.
4. Felsenstein D, D’Amico DJ, Hirsch MS, Neumeyer DA, Cederberg DM, de Miranda P, Schooley RT. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-l-(hydroxymethyl) ethoxymethyljguanine. Ann Intern Med 1985;103:377-80.
5. Bach MC, Bagwell SP, Knapp NP, Davis KM, Hedstrom PS. 9-(l, 3-dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:381-2.
6. Masur H, Lane HC, Palestine A, Smith PD, Manischewitz J, Stevens G, Fujikawa L, Macher AM, Nussenblatt R, Baird B, Megill M, Wittek A, Quinnan GV, Parrillo JE, Rook AH, Eron LJ, Poretz DM, Goldenberg RI, Fauci AS, Geiman EP. Effect of 9-(l, 3-dihydroxy-2-propoxy-methyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 1986;104:41-4.
7. Palestine AG, Stevens G Jr, Lane HC, Masur H, Fujikawa LS, Nussenblatt RB, Rook AH, Manischewitz J, Baird B, Megill M, Quinnan G, Gelmann E, Fauci AS. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol 1986;101:95-101.
8. Kotler DP, Culpepper-Morgan JA, Tierney AR, Klein EB. Treatment of disseminated cytomegalovirus infection with 9-(l, 3-dihydroxy-2-propoxymethyl)guanine; evidence of prolonged survival in patients with the acquired immunodeficiency syndrome. AIDS Res 1986;2:299-308.
9. Laskin OL, Stahl-Bayliss CM, Kaiman CM, Rosecin LR. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis 1987;155:323-7.
10. Shepp DH, Dandliker PS, de Miranda P, Burnette TC, Cederberg DM, Kirk LE, Meyers JD. Activity of 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103: 368-73.
11. Reed EC, Dandliker PS, Meyers JD. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-l-(hydroxymethyl)eth-oxymethyljguanine and high-dose corticosteroids. Ann Intern Med 1986;105:214-5.
12. Bratanow N, Ash R, Turner P, Smith R, Chitambar C, Hansen R, Casper J. Successful treatment of serious cytomegalovirus disease with DHPG in bone marrow transplant patients [abstract]. Blood 1986;68(Suppl l):280a.
13. Erice A, Jordan C, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987;257:3082-7.
14. Collier AC, Meyers JD, Corey L, Murphy VL, Roberts PL, Handsfield HH. Cytomegalovirus infection in homosexual men: Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med 1987;82:593-601.
15. Drew WL, Brodie H, Conant M, Volberding P, Rumack J. Diagnosis and treatment of cytomegalovirus (CMV) infection. In: Mills J. Corey L, eds. Antiviral chemotherapy: New directions for clinical application and research. New York: Elsevier, 1986:280-9.
16. Holland GN, Sidikaro Y, Kreiger AE, Hardy D, Sakamoto MJ, Frenkel LM, Winston DJ, Gottlieb MS, Bryson YJ, Champlin RE, Ho WG, Winters RE, Wolfe PR, Cherry JD. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987;94:815-23.
17. Jabs DA, Newman C, De Bustros S, Polk BF. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94:824-30.
18. Orellana J, Teich SA, Friedman AH, Lerebours F, Winterkorn J, Mildvan D. Combined shortand long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987;94:831-8 S503.
19. Laskin OL, Cederberg DM, Mills J, Eron LJ, Mildvan D, Spector SA. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987;83:201-7.
20. Chachoua A, Dieterich D, Krasinski K, Greene J, Laubenstein L, Wernz J, Buhles W, Koretz S. 9-(l, 3-dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med 1987;107: 131-7 S504.